Tech Transfer Agrifood (TTAF), fondo dirigido por la gestora de capital riesgo, Clave Capital, hainvertido en la empresa BIOQUOCHEM S.L -BQC Redox Technologies- para el lanzamiento de su aplicación m...
BeAble Capital, gestora de fondos especializada en Science Equity (Transferencia Tecnológica en Deep Science) ha identificado las enormes posibilidades de Next-Gen Leather y su tecnología BacLEATHER...
La Xunta de Galicia, a través de Xesgalicia, ha formalizado una inversión de 1,25 millones de euros para que Iffe Biotech pueda finalizar sus instalaciones en As Somozas (A Coruña) y lanzar al merc...
ENDRA and CDTI Innvierte lead the new investment bringing up to €7million the total funds raised by the company in the last year, together with current investors Sabadell Asabys, Caixa Capital Risc ...
La gestora de capital riesgo Clave Capital participa, a través de su fondo Mondragon Fondo de Promoción FCR, en la ronda de financiación de la startup biotecnológica Insekt Label Biotech por un im...
XesGalicia, organismo inversor dependiente de la Xunta de Galicia, participará, a través de su fondo Galicia InnovaTech, en una ronda de financiación de la compañía biotecnológica Oncostellae - ...
Inveready, gestora de capital riesgo líder en España, ha realizado una inversión de 4,5 millones de euros en Devon Labs a través de sus fondos Inveready Biotech III e Inveready Venture Finance III...
Agomab Therapeutics NV (‘Agomab’) has announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount raised ...
Dialogue with investors is no easy task for entrepreneurs in the healthcare sector. We will focus more on how to negotiate a round in the health Venture Capital investor sector in this article, and...
Henko Capital Partners, Spanish private equity firm, has invested in BioClever to drive its international growth. Henko seeks to position BioClever as a comprehensive partner for clinical trials and r...
Headquartered in Barcelona, Asabys was founded by Josep Ll. Sanfeliu and Clara Campàs in 2018 with the support of Alantra as strategic partner. Banc Sabadell, who was the anchor investor of the firm
SparingVision, a genomic medicine company developing vision-saving treatments for ocular diseases, today announces that it has raised €75 million in a Series B financing. The round was co-led by Jei...